Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Antenatal Steroids for Preterm Birth is Cost Effective

Key clinical point: Antenatal betamethasone cost-effectively improved infant outcomes among pregnant women at high risk for preterm birth.

Major finding: Antenatal betamethasone treatment was linked to $4,681 per mother-infant pair, compared with $5,379 without corticosteroids (P = .02 for $698 difference).

Study details: The findings are based on a secondary analysis of a randomized clinical trial from October 2010 to February 2015 involving 2,821 mothers at high risk for preterm birth, and their infants.

Disclosures: The National Institutes of Health funded the research. Dr. Gyamfi-Bannerman received a grant from AMAG pharmaceuticals during the conduct of the study.

Citation:

Gyamfi-Bannerman C. JAMA Pediatr. 2019 Mar 11. doi: 10.1001/jamapediatrics.2019.0032.